AMAG Shareholders Reject $268M Allos Merger
AMAG Pharmaceuticals Inc. shareholders on Friday rejected the company's proposed $268 million, all-stock acquisition of lymphoma-drug maker Allos Therapeutics Inc....To view the full article, register now.
Already a subscriber? Click here to view full article